01 Modular Spectral Systems Expand High-Parameter Analysis Flow cytometry is shifting toward modular spectral systems that let laboratories add high-parameter capability without replacing an entire instrument. Spectral detection records the full emission pattern of each fluorochrome, helping researchers separate overlapping signals and design larger antibody panels. Modular hardware allows laboratories to expand detection channels as research needs and budgets change. This approach protects earlier equipment investments while supporting detailed analysis of immune cells, tumours, and treatment responses. The mechanism reduces the barrier to adopting advanced cytometry and increases demand for compatible lasers, detectors, reagents, and analysis software. Competition is therefore moving toward flexible configurations, higher throughput, automation, and easier management of complex data. In March 2025, a modular spectral detection system offering up to 88 detection channels was introduced for laboratories seeking expandable cell-analysis capability.
01 Cell and Gene Therapies Require Detailed Quality Testing Growth in cell and gene therapy is increasing demand for detailed cell identification, counting, and quality testing. Developers use flow cytometry to confirm therapeutic cell identity, measure purity, examine viability, detect unwanted populations, and monitor immune responses during clinical studies. These tests are essential when treatments are manufactured from living cells whose characteristics can change across processing stages. Expanding regulatory pathways and clinical programs therefore create recurring demand for instruments, antibodies, controls, software, and contract laboratory services. The mechanism extends beyond initial research because approved therapies require batch testing and patient monitoring. Suppliers that provide validated workflows and regulatory documentation can support development, manufacturing, release testing, and post-treatment assessment.
01 High Instrument and Operating Costs Limit Adoption High equipment and operating costs limit advanced flow cytometry adoption among smaller hospitals, universities, and laboratories. A spectral analyser or cell sorter may require substantial capital funding, specialized rooms, maintenance agreements, calibration materials, antibodies, and trained operators. Complex experiments also consume expensive reagents and create large datasets that need skilled analysis. An institution may therefore share a core facility, outsource testing, or delay replacing an older system instead of purchasing equipment directly. This reduces the number of potential buyers and lengthens sales cycles. Vendors must demonstrate high utilization and measurable productivity gains, while laboratories need dependable funding for installation, training, service, consumables, and long-term instrument support.
01 Nanoscale Cytometry Opens New Research Applications Nanoscale flow cytometry creates a new opportunity to study extracellular vesicles, viruses, drug-delivery particles, and other objects that conventional instruments struggle to detect. These particles can contain biological signals linked to disease, immune responses, and treatment effects, making them valuable in biomarker discovery and therapeutic development. Purpose-built systems now claim detection of particles as small as 40 nanometres while measuring several fluorescent and light-scatter characteristics. This extends flow cytometry into research areas previously served mainly by microscopy or separate particle-analysis methods. The mechanism opens demand for sensitive detectors, specialized calibration materials, nanoparticle reagents, analysis software, and research services across oncology, vaccines, diagnostics, and advanced drug delivery.
01 Interlaboratory Variability Complicates Result Comparison Producing comparable flow cytometry results across laboratories remains difficult because instruments, reagents, sample preparation, compensation methods, and analysis gates can differ. Even small changes in staining time, detector settings, cell handling, or operator decisions may alter the reported population. The problem becomes greater in multicentre clinical trials and regulated testing, where results must remain consistent across sites and over time. Laboratories need standardized protocols, reference controls, daily quality checks, proficiency testing, and documented analysis methods. These activities increase workload and require continued training. Without strong harmonization, data may be difficult to combine, biomarkers may fail validation, and diagnostic or therapeutic decisions may become less reliable.
September 2025 BD continued expanding its flow cytometry ecosystem through advancements in high-parameter analysis, spectral flow cytometry, and integrated single-cell analysis solutions. The company focused on improving research capabilities in immunology, oncology, and cell therapy development
August 2025 Curiox Biosystems and Calebio expanded their strategic partnership to accelerate adoption of automated flow cytometry workflows in China. Under the agreement, Calebio became an exclusive distributor of Curiox’s Pluto Workstation platform in mainland China, supporting automation in sample preparation and full-spectrum flow cytometry applications.
July 2025 Waters Corporation and BD announced a definitive agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters through a Reverse Morris Trust transaction valued at approximately USD 17.5 billion. The combination strengthened Waters’ position in life science technologies, including flow cytometry, diagnostics, and analytical solutions.
June 2025 Beckman Coulter Life Sciences expanded its flow cytometry capabilities through its partnership with Rarity Bioscience AB to distribute superRCA® technology assays. The collaboration combined molecular detection technology with flow cytometry workflows to improve high-sensitivity mutation detection for oncology research and clinical applications.